Noventure, as part of its ongoing activities in support of the launch of Gelsectan®, participated with a stand at the IBS Days 2018 in Bologne, Italy, May 17 - 19, 2018.
This meeting is intended to provide current views and a look to the future on the rapidly advancing field of IBS. One of the lectures was devoted to mucosal barrier and permeability, which is a hot topic among gastroenterologists specialized in IBS management.
Gelsectan® contains mucoprotectors which improve the resistance of the mucosal barrier and help restore its normal function. It is intended to relieve and prevent IBS symptoms such as chronic or relapsing diarrhoea, pain and bloating.
Gelsectan® is a class IIa medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0476, Noventure SL).
In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.